Literature DB >> 14700620

CDK versus GSK-3 inhibition: a purple haze no longer?

Peter M Fischer1.   

Abstract

The ubiquitous ATP binding site offers a global target for protein kinase inhibitors. The corollary is that molecular selectivity with such agents may be difficult to achieve and ascertain. A relevant example is discussed in terms of design and biomedical rationale.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14700620     DOI: 10.1016/j.chembiol.2003.12.009

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  4 in total

1.  Essential roles for GSK-3s and GSK-3-primed substrates in neurotrophin-induced and hippocampal axon growth.

Authors:  Woo-Yang Kim; Feng-Quan Zhou; Jiang Zhou; Yukako Yokota; Yan-Min Wang; Takeshi Yoshimura; Kozo Kaibuchi; James R Woodgett; E S Anton; William D Snider
Journal:  Neuron       Date:  2006-12-21       Impact factor: 17.173

2.  Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors.

Authors:  Prerna Diwan; Jonathan J Lacasse; Luis M Schang
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

Review 3.  Glycogen synthase kinase 3: more than a namesake.

Authors:  Geetha Vani Rayasam; Vamshi Krishna Tulasi; Reena Sodhi; Joseph Alex Davis; Abhijit Ray
Journal:  Br J Pharmacol       Date:  2009-03-04       Impact factor: 8.739

4.  GSK3beta Inhibitor Peptide Protects Mice from LPS-induced Endotoxin Shock.

Authors:  Ryeojin Ko; Hyun Duk Jang; Soo Young Lee
Journal:  Immune Netw       Date:  2010-06-30       Impact factor: 6.303

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.